A Review on Iron Chelators in Treatment of Iron Overload Syndromes
Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs such as liver and heart after regular transfusion. In this review, different iron chelators implicated in treatment of iron overload in various clinical conditions have been evaluated using more up-to-date studies focusing on these therapeutic agents. Deferoxamine, Deferiprone and Deferasirox are the most important specific US FDA-approved iron chelators. Each of these chelators has their own advantages and disadvantages, various target diseases, levels of deposited iron and clinical symptoms of the afflicted patients which may affect their selection as the best modality. Taken together, in many clinical disorders, choosing a standard chelator does not have an accurate index which requires further clarifications. The aim of this review is to introduce and compare the different iron chelators regarding their advantages and disadvantages, usage dose and specific applications.
Angelucci E. Another Step Forward in Iron Chelation Therapy. Acta Haematol. 2015; 134(4):231-2.
Leitch HA. Hematologic improvement with Iron chelation therapy in acquired anemias. Eur J Haematol. 2016; 96(6):551-2.
Kontoghiorghe CN, Kontoghiorghes GJ. New developments and controversies in iron metabolism and iron chelation therapy. World J Methodol. 2016; 6(1):1-19.
Poggiali E, Cassinerio E, Zanaboni L, et al. An update on iron chelation therapy. Blood Transfus. 2012; 10(4):411-22.
Ghorban K, Shanaki M, Mobarra N, et al. Apolipoproteins A1, B, and other prognostic biochemical cardiovascular risk factors in patients with beta-thalassemia major. Hematology. Hematology. 2016; 21(2):113-20.
Fedele R, Cuzzola M, Irrera G, et al. Polycythemia following allogeneic hematopoietic progenitor cell transplantation occurring during iron chelation therapy. Leuk Lymphoma. 2016; 57(4):969-72.
Diamantidis MD, Neokleous N, Agapidou A, et al. Iron chelation therapy of transfusion-dependent beta-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic? Int J Hematol. 2016; 103(5):537-44.
Efficace F, Santini V, La Nasa G, et al. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. BMJ Support Palliat Care. 2016; 6(1):80-8.
Salgia RJ, Brown K. Diagnosis and management of hereditary hemochromatosis. Clin Liver Dis. 2015; 19(1):187-98.
Altes A, Sanz C, Bruguera M. Hereditary hemochromatosis. Problems in diagnosis and treatment. Medicina Clinica. 2015; 144(9):424-8.
Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994; 331(9):567-73.
Belhoul KM, Bakir ML, Kadhim AM, et al. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre. Ann Saudi Med. 2013; 33(1):18-21.
De Sanctis V, Giovannini M. Endocrine histology findings in a prepubertal thalassemic girl with multiple endocrine complications secondary to iron overload. Georgian Med News. 2011; (193):51-5.
Bajoria R, Chatterjee R. Hypogonadotrophic hypogonadism and diminished gonadal reserve accounts for dysfunctional gametogenesis in thalassaemia patients with iron overload presenting with infertility. Hemoglobin. 2011; 35(5-6):636-42.
Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis. 2011; 47(1):33-40.
Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol. 2011; 90(1):1-10.
Liu Q, Sun L, Tan Y, et al. Role of iron deficiency and overload in the pathogenesis of diabetes and diabetic complications. Curr Med Chem. 2009; 16(1):113-29.
Remacha AF, Arrizabalaga B, Villegas A, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol. 2015; 94(5):779-87.
Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000; 110(4):971-7.
Xiao W, Beibei F, Guangsi S, et al. Iron overload increases osteoclastogenesis and aggravates the effects of ovariectomy on bone mass. J Endocrinol. 2015; 226(3):121-34.
Ehteram H, Bavarsad MS, Mokhtari M, et al. Prooxidant-antioxidant balance and hs-CRP in patients with beta-thalassemia major. Clin Lab. 2014; 60(2):207-15.
Senol SP, Tiftik EN, Unal S, et al. Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy. J Basic Clin Pharm. 2016; 7(2):49-59.
Li Y, Qin J, Wei X, et al. The Risk Factors of Child Lead Poisoning in China: A Meta-Analysis. Int J Environ Res Public Health. 2016; 13(3): pii: E296.
Gu CH, Li CX, Ye L, et al. Effects of iron chelation therapy on allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome patients with iron overload. Zhonghua Xue Ye Xue Za Zhi. 2016; 37(3):189-93
Rodrigues S, Almeida A, Viriato D, et al. Real-World Evidence of Iron Chelation Therapy In Transfusion-Dependent Mds Patients: A Portuguese Hospital Registry. Value Health. 2015; 18(7):A659.
Kochhar H, Leger CS, Leitch HA. Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy. Case Reports in Hematology. 2015(2015):1-7.
Taher AT, Cappellini MD, Aydinok Y, et al. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells Mol Dis. 2016; 57:23-9.
Jordan L, Adams-Graves P, Kanter-Washko J, et al. Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy. Curr Med Res Opin. 2015; 31(3):513-23.
Vekeman F, Cheng WY, Sasane M, et al. Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy. Leuk Lymphoma. 2015; 56(10):2803-11.
Shamsian BS, Esfahani SA, Milani H, et al. Magnetic resonance imaging in the evaluation of iron overload: a comparison of MRI, echocardiography and serum ferritin level in patients with beta-thalassemia major. Clin Imaging. 2012; 36(5):483-8.
Ware HM, Kwiatkowski JL. Evaluation and treatment of transfusional iron overload in children. Pediatr Clin North Am. 2013; 60(6):1393-406.
Wood JC, Glynos T, Thompson A, et al. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica. 2011; 96(7):1055-8.
Mavrogeni S, Markousis-Mavrogenis G, Markussis V, et al. The Emerging Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Metabolic Cardiomyopathies. Horm Metab Res. 2015; 47(9):623-32.
Meloni A, Ramazzotti A, Positano V, et al. Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia. Int J Med Inform. 2009; 78(8):503-12.
Pitt CG, Gupta G, Estes WE, et al. The selection and evaluation of new chelating agents for the treatment of iron overload. J Pharmacol Exp Ther. 1979; 208(1):12-8.
Ricchi P, Ammirabile M, Spasiano A, et al. Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy. Acta Haematol. 2010; 123(2):117-20.
Junqueira FP, Fernandes JL, Cunha GM, et al. Right and left ventricular function and myocardial scarring in adult patients with sickle cell disease: a comprehensive magnetic resonance assessment of hepatic and myocardialiron overload. J Cardiovasc Magn Reson. 2013; 15:83.
Hassan MA, Tolba OA. Iron chelationmonotherapy in transfusion-dependent beta-thalassemiamajorpatients: a comparative study of deferasirox and deferoxamine. Electron Physician. 2016; 8(5):2425-31.
Vekeman F, Sasane M, Cheng WY, et al. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia. J Med Econ. 2016; 19(3):292-303.
Uygun V, Kurtoglu E. Iron-chelation therapy with oral chelators in patients with thalassemia major. Hematology. 2013; 18(1):50-5.
Kuo KH, Mrkobrada M. A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with beta-thalassemia. Hemoglobin. 2014; 38(6):409-21.
Cui HJ, He HY, Yang AL, et al. Efficacy of deferoxamine in animal models of intracerebral hemorrhage: a systematic review and stratified meta-analysis. PloS one. 2015; 10(5):e0127256.
Arandi N, Haghpanah S, Safaei S, Z et al. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources. Transf Med. 2015; 25(1):8-12.
Voskaridou E, Komninaka V, Karavas A, et al. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with beta-thalassemia major and severe iron burden. Transfusion. 2014; 54(3):646-9.
Sane A, Manzi S, Perfect J, et al. Deferoxamine treatment as a risk factor for zygomycete infection. The J Infect Dis. 1989; 159(1):151-2.
Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag. 2007; 3(5):795–805.
Kontoghiorghes GJ. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review. Analyst. 1995; 120(3):845-51.
Addis A, Loebstein R, Koren G, et al. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol. 1999; 55(1):1-6.
Caro J, Huybrechts KF, Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review. BMC Blood Disord. 2002; 2(1):4.
Mattioli F, Puntoni M, Marini V, et al. Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy? Eur J Haematol. 2015; 94(4):310-7.
Sharma A, Arora E, Singh H. Hypersensitivity reaction with deferasirox. J Pharmacol Pharmacother. 2015; 6(2):105-6.
Al-Khabori M, Bhandari S, Al-Huneini M, et al. Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia. Oman Med J. 2013; 28(2): 121–24.
Kolnagou A, Economides C, Eracleous E, et al. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008; 32(1-2):41-7.
Bauchner H, Fontanarosa PB, Golub RM. Evaluation of the Trial to Assess Chelation Therapy (TACT): the scientific process, peer review, and editorial scrutiny. JAMA. 2013; 309(12):1291-2.
Pavenski K, Quirt I. The real cost of iron chelation therapy. Transfusion. 2007; 47(10):1751-2.
Delea TE, Sofrygin O, Thomas SK, et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalass aemia patients: US healthcare system perspective. Pharmacoeconomics. 2007; 25(4):329-42.
Karnon J, Tolley K, Oyee J, et al. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin. 2008; 24(6):1609-21.
Suzuki T. Iron overload and iron chelation therapy. Rinsho Ketsueki. 2012; 53(1):25-35.
Pippard MJ. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies. Acta Haematologica. 1987; 78(2-3):206-11.
Malcovati L. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S305-11
Delforge M, Selleslag D, Beguin Y, et al. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res. 2014; 38(5):557-63.
Kontoghiorghes GJ, Spyrou A, Kolganou A. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption Hemoglobin. 2010; 34(3):251-64.
Sahmani M, Vatanmakanian M, Goudarzi M, et al. Microchips and their Significance in Isolation of Circulating Tumor Cells and Monitoring of Cancers. Asian Pac J Cancer Prev. 2016; 17(3):879-94.
Saletta F, Kovacevic Z, Richardson DR. Iron chelation: deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules. Future Med Chem. 2011; 3(16):1983-6.